Merck KGaA (FRA:MRK) received a €82.00 ($95.35) price objective from stock analysts at Barclays in a research report issued on Tuesday, Borsen Zeitung reports. The brokerage presently has a “sell” rating on the healthcare company’s stock. Barclays‘s price objective suggests a potential downside of 9.99% from the company’s current price.
Other equities research analysts have also issued research reports about the company. DZ Bank reissued a “neutral” rating on shares of Merck KGaA in a report on Tuesday, April 2nd. Sanford C. Bernstein set a €108.00 ($125.58) price objective on Merck KGaA and gave the stock a “neutral” rating in a report on Monday, April 15th. JPMorgan Chase & Co. set a €100.00 ($116.28) target price on Merck KGaA and gave the company a “neutral” rating in a report on Monday. UBS Group set a €104.00 ($120.93) target price on Merck KGaA and gave the company a “neutral” rating in a report on Monday. Finally, Kepler Capital Markets set a €110.00 ($127.91) target price on Merck KGaA and gave the company a “buy” rating in a report on Monday, April 1st. One analyst has rated the stock with a sell rating, fifteen have issued a hold rating and five have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average price target of €101.10 ($117.56).
Shares of MRK opened at €91.10 ($105.93) on Tuesday. Merck KGaA has a fifty-two week low of €76.60 ($89.07) and a fifty-two week high of €115.00 ($133.72).
Merck KGaA Company Profile
MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. It offers prescription medicines to treat cancer, multiple sclerosis, infertility, growth deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, as well as squamous cell carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments.
Recommended Story: What are municipal bonds?
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.